All In Biotech

Free tool

FAERS Monitor: Gallium Ga 68 Gozetotide

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212643 or its brand name (Gallium Ga 68 Gozetotide, Gallium Ga-68 Gozetotide). Reports on generic versions are filed under their own applications.

Reports

204

Serious

144

71% of reports

Hospitalization

65

Death reported

20

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hot flush36
  • erectile dysfunction27
  • fatigue15
  • death11
  • overdose9
  • pathological fracture9
  • aspartate aminotransferase increased8
  • asthenia8
  • rash8
  • cerebral amyloid angiopathy7
  • drug interaction7
  • muscular weakness7
  • alanine aminotransferase increased6
  • hyperhidrosis6
  • hypothyroidism6

Reports by year received

View as table
YearReports
202210
20236
20247
2025129
202652

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,955 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cerebral amyloid angiopathySignal72236.71071.313,201
pathological fractureSignal9183.296.61,451
erectile dysfunctionSignal27108.576.42,771
hot flushSignal3649.336.61,660
hypothyroidismSignal619.48.887
aspartate aminotransferase increasedSignal815.57.995
alanine aminotransferase increasedSignal610.14.641
muscular weaknessSignal76.43.127
hyperhidrosisSignal64.82.215
drug interactionSignal74.52.216
overdoseSignal94.32.320
astheniaSignal82.21.14
fatigue152.01.27
rash81.91.03
death111.30.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.